Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Study Group: Physicians who Treat Depression (US)

Council Members in this Study Group: 450

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Contact Gerson Lehrman Group to survey or consult with members of this Study Group

Leading institutions connect with members of this Study Group through GLG

Leading Experts in this Study Group

Ara Dikranian, MD

Partner and Rheumatologist
San Diego Arthritis Medical Clinic
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Ara Dikranian, MD, is Partner and Rheumatologist at San Diego Arthritis Medical Clinic, a single-specialty private practice in San Diego, California. Dr. Dikranian is board certified in internal medicine and rheumatology. He completed his rheumatology training at the University of California San Diego....

Daniel Wynn, MD, Director of Clinical Research, CONSULTANTS IN NEUROLOGY LTDDaniel Wynn, MD

Director of Clinical Research
CONSULTANTS IN NEUROLOGY LTD
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Daniel Wynn, MD, FACN, FAASM, is a Director of Clinical Research at Consultants in Neurology in Chicago, Illinois. He has expertise in a wide variety of neurological illnesses and has served as a principal investigator in over 100 clinical trials in multiple sclerosis, Alzheimer's disease, stroke,chronic...

Marina Raikhel, MD, Director, TORRANCE MEMORIAL MEDICAL CENTERMarina Raikhel, MD

Director
TORRANCE MEMORIAL MEDICAL CENTER
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Marina Raikhel, MD, is an active family practitioner with a particular interest in primary care and ob/gyn focus. She has expertise in the treatment of a wide variety of internal medicine conditions, with special focus on diabetes, hypertension, obesity, anxiety, and depression. She is Director ofTorrance...

David Portman, MD, Director, COLUMBUS CENTER FOR WOMENS HEALTH RESEARCHDavid Portman, MD

Director
COLUMBUS CENTER FOR WOMENS HEALTH RESEARCH
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

David Portman, MD, is Director and Principal Investigator of the Columbus Center for Women's Health Research. Dr. Portman is also a Clincial Investigator at The Ohio State University. He has conducted over 100 clinical studies in areas of contraception, osteoporosis, menopause, and sexual dysfunction...

David Rosenberg, MD

Chief of Psychiatry and Psychology
CHILDREN'S HOSPITAL OF MICHIGAN
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

David Rosenberg, MD, is a tenured Professor and Miriam L Hamburger Endowed Chair of Psychiatry at Wayne State University and the Children's Hospital of Michigan. He is a board certified general and adult psychiatrist and pediatric psychiatrist. Dr. Rosenberg has authored first ever textbook on pediatric...

John Litton Jr., MD, Chief Executive Officer and President, Litton Family Medicine, PCJohn Litton Jr., MD

Chief Executive Officer and President
Litton Family Medicine, PC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

J. Scott Litton, Jr., MD, FAAFP, is the Chief Executive Officer and President of Litton Family Medicine, PC in Pennington Gap, VA. He provides inpatient services and also serves as the Medical Director of the Center for Wound Care at Lee Regional Medical Center. Dr. Litton serves as a Faculty member...

Amit Vijapura, MD, Owner, AMIT VIJAPURA MDAmit Vijapura, MD

Owner
AMIT VIJAPURA MD
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Amit Vijapura, MD, is a Private Practitioner in Psychiatry based in Florida. He has over 15 years of experience in the field and has expertise in depression, bipolar disorder, anxiety disorder, attention deficient disorder, and schizophrenia. Dr. Vijapura is board certified in Psychiatry and is also...

Robert Schulte

Psychiatrist
North Scottsdale Psychiatric Specialists
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Robert Schulte, MD, is a Private Practitioner and a Psychiatrist at North Scottsdale Psychiatric Specialists in Arizona. He is board certified in Adult Psychiatry and Child and Adolescent Psychiatry with extensive experience with children and adult's re-psychotherapy and psychopharmacology and thetreatment...

View all Leading Experts in this Study Group

GLG NewsSM Analyses by this Study Group's Leading Experts (?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

We need to learn more about ProSavin Phase I/II Trial in Parkinson’s disease

October 20, 2009

Oxford BioMedica Announces Update on ProSavin® Phase I/II Trial in Parkinsons Disease And Publication of Preclinical Results | www.pipelinereview.com

This is very interesting news. However, in my judgment it is too early to make a final conclusion concerning this clinical trial. Because it should be taken into account that the growing body of evidence clearly indicates that oxidative stress induced mitochondrial failure appeared to be one of the...

Amyloid Beta does not correlate to Alzheimer Disease.

October 12, 2009

Bayer Schering ties-up with AC Immune for trial in Alzheimer´s disease | www.pharmabiz.com

The finding of amyloid-beta (Aβ) deposition in AD brains after death led to the so-called “amyloid hypothesis”.  We have extensively reviewed the literature which claims that AD is caused by the deposition of Aβ within structures called senile plaques that invade AD brains and that such plaque formation...

Antidepressants Vary More in Side Effects, Not Efficacy

August 30, 2009

2nd Generation Antidepressants Prove Effective | health.usnews.com

[SIDE EFFECTS] The main differences among the newer antidepressants are side effects and drug interactions.  See the Commentary for a drug-by-drug list of these key differences. [PCP's] This review comes from a group of primary care docs, which is important because most depression is treated by PCPs....

State Medicaid Cuts May Limit Market for New Antipsychotic Lurasidone

August 30, 2009

LURASIDONE DEMONSTRATED EFFICACY IN TREATING PATIENTS WITH SCHIZOPHRENIA IN PIVOTAL PHASE 3 STUDY | www.pipelinereview.com

Lurasidone is an atypical antipsychotic owned by Dainippon Sumitomo Pharma. Phase 3 PEARL 1 Study: 6-week, multi-site, double-blind placebo-controlled trial in 500 pts with DSM4 schizophrenia with PANSS score greater than 80. RESULTS: 80mg dose was superior to placebo; 40mg & 120mg was not....

Lurasidone will be an important new option for the treatment of Schizophrenia

August 29, 2009

LURASIDONE DEMONSTRATED EFFICACY IN TREATING PATIENTS WITH SCHIZOPHRENIA IN PIVOTAL PHASE 3 STUDY | www.pipelinereview.com

 After much disappointment over the current Atypical Antipsychotics , Lurasidone shows great promise for treatment refractory Schizophrenics.

View All GLG News by members of this Study Group

Members in this Study Group include these company types:

  • Office Based Private Practice or Clinic
  • Academic Medical Center/Hospital or Clinic
  • Non-Academic Community Hospital or Clinic

Members in this Study Group often have these job titles:

  • Physician - Attending Physician
  • Owner
  • Physician - Director
  • President
  • Director
  • Medical Director